Log in to save to my catalogue

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic ur...

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic ur...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1979963179

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

About this item

Full title

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

Publisher

England: Elsevier Ltd

Journal title

The Lancet (British edition), 2018-02, Vol.391 (10122), p.748-757

Language

English

Formats

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

Few options exist for patients with locally advanced or metastatic urothelial carcinoma after progression with platinum-based chemotherapy. We aimed to assess the safety and efficacy of atezolizumab (anti-programmed death-ligand 1 [PD-L1]) versus chemotherapy in this patient population.
We conducted this multicentre, open-label, phase 3 randomis...

Alternative Titles

Full title

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_1979963179

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1979963179

Other Identifiers

ISSN

0140-6736

E-ISSN

1474-547X

DOI

10.1016/S0140-6736(17)33297-X

How to access this item